UBS analyst Ashwani Verma lowered the firm’s price target on Cytokinetics (CYTK) to $41 from $47 and keeps a Neutral rating on the shares. Cytokinetics has had a series of setbacks, and differentiation appears increasingly to be a pipe dream, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics Receives Buy Rating from Analyst Joseph Pantginis Due to Promising Developments and Strategic Market Positioning
- Cytokinetics’ Aficamten Faces Market Uncertainty Amid FDA Delays, Prompting Hold Rating
- Cytokinetics falls 12% to $37.91 after FDA delays aficamten review
- Cytokinetics announces PDUFA action date for aficamten
- Insider Moves: HEICO, Pegasystems, Transdigm, Cytokinetics, LKQ